Scisco Genetics Inc

sciscogenetics.com

Scisco Genetics Inc, a Seattle-based spin-off from the Fred Hutchinson Cancer Research Center, is a leading provider of sequencing services for complex immune regions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

NOVO HOLDINGS LEADS US$21M SERIES A FINANCING IN BIOMILQ

Novo Holdings | October 21, 2021

news image

BIOMILQ is developing a novel infant feeding option, derived from human mammary cells, to better meet infants' nutritional needs and with a lower carbon footprint than traditional bovine-based infant formula. Earlier this year, BIOMILQ announced it had successfully produced a milk product with many of the same macronutrients that are known to be abundantly present in breastmilk in its lab based in Research Triangle Park in North Carolina, US. In the US, it is estim...

Read More

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

news image

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More

MEDICAL

ALGAENERGY AGREEMENTS WITH LABORATOIRE M2 FOR DISTRIBUTION AND PRODUCT DEVELOPMENT

AlgaEnergy | January 14, 2021

news image

AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. furthermore, a worldwide pioneer in microalgae biotechnology, has marked worldwide item conveyance and item improvement concurrences with Laboratoire M2 Inc., a Quebec-based biotechnology organization that creates normal and practical disinfectant items, including THYMOX CONTROL® fungicide and bactericide. AlgaEnergy formulates and creates incredible, manageable, microalgae-based yield contributions for t...

Read More

CELL AND GENE THERAPY

BIOMARIN AND SKYLINE THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL GENE THERAPIES FOR CARDIOVASCULAR DISEASES

BioMarin Pharmaceutical Inc. | December 17, 2021

news image

BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...

Read More
news image

INDUSTRIAL IMPACT

NOVO HOLDINGS LEADS US$21M SERIES A FINANCING IN BIOMILQ

Novo Holdings | October 21, 2021

BIOMILQ is developing a novel infant feeding option, derived from human mammary cells, to better meet infants' nutritional needs and with a lower carbon footprint than traditional bovine-based infant formula. Earlier this year, BIOMILQ announced it had successfully produced a milk product with many of the same macronutrients that are known to be abundantly present in breastmilk in its lab based in Research Triangle Park in North Carolina, US. In the US, it is estim...

Read More
news image

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More
news image

MEDICAL

ALGAENERGY AGREEMENTS WITH LABORATOIRE M2 FOR DISTRIBUTION AND PRODUCT DEVELOPMENT

AlgaEnergy | January 14, 2021

AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. furthermore, a worldwide pioneer in microalgae biotechnology, has marked worldwide item conveyance and item improvement concurrences with Laboratoire M2 Inc., a Quebec-based biotechnology organization that creates normal and practical disinfectant items, including THYMOX CONTROL® fungicide and bactericide. AlgaEnergy formulates and creates incredible, manageable, microalgae-based yield contributions for t...

Read More
news image

CELL AND GENE THERAPY

BIOMARIN AND SKYLINE THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL GENE THERAPIES FOR CARDIOVASCULAR DISEASES

BioMarin Pharmaceutical Inc. | December 17, 2021

BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...

Read More